United Therapeutics' pipeline and Tyvaso DPI drive strong growth. Read why UTHR stock offers substantial upside with ...

Liquidia's collaboration on L606 boosts long-term growth potential. Find out why LQDA stock’s valuation and upcoming launches ...

United Therapeutics’ UTHR third-quarter 2024 earnings of $6.39 per share beat the Zacks Consensus Estimate of $6.18. Earnings ...

multi-center phase 3 clinical study of YUTREPIA in patients diagnosed with PAH who are naïve to inhaled treprostinil or who are transitioning from Tyvaso® (nebulized treprostinil). YUTREPIA is ...

We are delighted by the interest from the global medical and patient communities, many of which lack access to inhaled formulations ... to 26 to 28 breaths of Tyvaso administered four times ...

Received tentative approval from the FDA for YUTREPIA™ (treprostinil) inhalation powder for both ... decision to grant three-year exclusivity to TYVASO DPI ®, which will expire on May 23 ...

Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today reported financial results for the third quarter ...